ClinicalTrials.gg
CompletedNCT05701995ARTISTYKUpdated Jun 3, 2026Results posted

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

A Phase 4 interventional study of Deucravacitinib and Placebo in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 38 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.

Enrollment
10th of 26
180 · median 102
Started
2023
with 3 others
Phase 4
8 of 26
2 open now
Registered
15th of 26
by date
Lead sponsor
18 of 26
Bristol-Myers Squibb

Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 10th largest by enrollment, is one of 4 that started in 2023, is one of 8 in phase 4, and was the 15th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About deucravacitinib

deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing deucravacitinib in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • plaque psoriasis
  • deucravacitinib
  • BMS-986165
  • Health related quality of life (HrQoL)
  • QoL (quality of life)
  • SOTYKTU
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
  • Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
  • ≥ 3% of Body Surface Area (BSA) involvement at the Screening Visit and Day 1
  • Dermatology Life Quality Index (DLQI) score > 5 at the Screening Visit and Day 1
  • Moderate-to-severe plaque psoriasis as defined by static Physician Global Assessment (s-PGA) ≥ 3 at the Screening Visit and Day 1

Exclusion criteria

Exclusion Criteria:

Target Disease Exceptions:

  • Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1

Other protocol-defined inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Deucravacitinib

    Drug: Deucravacitinib

  • Placebo comparator
    Placebo then Deucravacitinib

    Drug: Deucravacitinib · Other: Placebo

Interventions

  • Specified dose on specified days.

    Also known as: BMS-986165, Sotyktu

  • OtherPlacebo

    Specified dose on specified days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16

    Dermatology Life Quality Index (DLQI) is a participant-reported Quality of Life (QoL) survey which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a 4-point scale: 0=not at all 1. a little 2. a lot 3. very much The scores are added up to give a total score between 0 and 30. A lower total score means a better quality of life.

    Time frame: At Week 16

Secondary outcomes

  1. Percentage of Participants Achieving a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

    The Dermatology Life Quality Index (DLQI) is a simple, 10-question survey used to measure the impact of skin conditions on a patient's quality of life. It assesses how much a skin condition affects various aspects of daily life, including symptoms, feelings, daily activities, work or school, personal relationships, and treatment. The DLQI is scored by summing the responses to its 10 questions. Each question is scored on a scale from 0 to 3: 0 = Not at all 1. = A little 2. = A lot 3. = Very much The total score ranges from 0 to 30, with higher scores indicating a greater impact on the patient's quality of life.

    Time frame: At Week 16

  2. Change From Baseline in Whole-body Itch Numerical Rating Scale (NRS) Score at Week 16

    The whole-body itch Numerical Rating Scale (NRS) is a survey that participants fill out themselves. It uses an 11-point scale from 0 to 10, where 0 means 'no itch' and 10 means 'worst itch imaginable.' Participants indicate the severity of their itching from psoriasis by selecting the number that best describes the worst level of itching they experienced in the past 24 hours. A lower score means better outcomes, indicating less severe itching.

    Time frame: Baseline and at Week 16

  3. Percentage of Participants With a Static Physician's Global Assessment (s-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16

    The Static Physician's Global Assessment (s-PGA) is a 5-point scale to evaluate the average severity of all psoriatic lesions based on redness, scaling, and thickness. The s-PGA measures psoriasis severity at a single point in time, without considering the initial condition. The scale rates the severity as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). A lower score means better outcomes, indicating less severe psoriasis.

    Time frame: At Week 16

  4. Number of Participants With Treatment Emergent Adverse Events (AEs) From Week 0 to Week 16

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

    Time frame: From Week 0 through Week 16

  5. Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) From Week 0 to Week 16

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From Week 0 through Week 16

  6. Number of Participants With Laboratory Abnormalities in Potential Drug-Induced Liver Injury Tests From Week 0 to Week 16

    Number of participants with laboratory abnormalities in potential drug-induced liver injury tests. ALT=Alanine aminotransferase AST=Aspartate aminotransferase ULN=Upper limit of normal

    Time frame: From Week 0 through Week 16

  7. Number of Participants With Grade 3/ Grade 4 Laboratory Abnormalities From Week 0 to Week 16

    Blood samples were collected to assess the abnormalities in laboratory parameters. The laboratory parameters were graded by Common Terminology Criteria for Adverse Events (CTCAE). Grade 3=Severe; Grade 4=Life-threatening.

    Time frame: From Week 0 through Week 16

  8. Number of Participants With Abnormalities in Vital Signs From Week 0 to Week 16

    Number of participants with abnormalities in vital signs including heart rate, systolic blood pressure, and diastolic blood pressure.

    Time frame: From Week 0 through Week 16

  9. Number of Participants With Clinically Significant Changes in Vital Signs From Week 0 to Week 16

    Vital Sign Measurements include: Body Temperature (C), Respiratory Rate (breaths/min), Seated Blood Pressure (mmHg) and Heart Rate (beats/min). Clinically significant changes in these measurements may need medical attention as they could indicate a potential health concern.

    Time frame: From Week 0 through Week 16

07

Results

Posted Sep 10, 2025

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestoneDeucravacitinibPlacebo
Started12060
Full analysis set sub-population10749
Completed11959
Not completed11
Withdrew: Randomization error11
Placebo Controlled: Week 0-16
Participant flow — Placebo Controlled: Week 0-16
MilestoneDeucravacitinibPlacebo
Started11959
Completed10449
Not completed1510
Withdrew: Withdrawal by subject84
Withdrew: Lost to follow-up23
Withdrew: Adverse event31
Withdrew: Other reason11
Withdrew: Death10
Withdrew: Physician decision01
Active Treatment: Week 16-52
Participant flow — Active Treatment: Week 16-52
MilestoneDeucravacitinibPlacebo
Started10349
Completed placebo controlled period; did not enter active treatment period10
Completed8741
Not completed168
Withdrew: Lost to follow-up54
Withdrew: Withdrawal by subject52
Withdrew: Lack of efficacy41
Withdrew: Adverse event01
Withdrew: Death10
Withdrew: Other reasons10

Outcome measures

PrimaryPercentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16

Dermatology Life Quality Index (DLQI) is a participant-reported Quality of Life (QoL) survey which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a 4-point scale: 0=not at all 1. a little 2. a lot 3. very much The scores are added up to give a total score between 0 and 30. A lower total score means a better quality of life.

Time frame:
At Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16
Percentage of ParticipantsDeucravacitinibPlacebo
Full Analysis Set33.3 (25.0 to 42.5)6.7 (1.8 to 16.2)
Full Analysis Set Sub-population32.7 (24.0 to 42.5)6.1 (1.3 to 16.9)
Statistical analysis
  • Deucravacitinib vs Placebo · Stratified Cochran-Mantel-Haenszel (CMH) · p = 0.0001 · Odds ratio (or): 7.7 · 95% CI 2.5 to 23.6
  • Deucravacitinib vs Placebo · Stratified Cochran-Mantel-Haenszel (CMH) · p = 0.0003 · Odds ratio (or): 8.5 · 95% CI 2.4 to 30.4
SecondaryPercentage of Participants Achieving a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

The Dermatology Life Quality Index (DLQI) is a simple, 10-question survey used to measure the impact of skin conditions on a patient's quality of life. It assesses how much a skin condition affects various aspects of daily life, including symptoms, feelings, daily activities, work or school, personal relationships, and treatment. The DLQI is scored by summing the responses to its 10 questions. Each question is scored on a scale from 0 to 3: 0 = Not at all 1. = A little 2. = A lot 3. = Very much The total score ranges from 0 to 30, with higher scores indicating a greater impact on the patient's quality of life.

Time frame:
At Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
Percentage of ParticipantsDeucravacitinibPlacebo
Full Analysis Set72.5 (63.6 to 80.3)53.3 (40.0 to 66.3)
Full Analysis Set Sub-population72.9 (63.4 to 81.0)53.1 (38.3 to 67.5)
Statistical analysis
  • Deucravacitinib vs Placebo · Stratified Cochran-Mantel-Haenszel (CMH) · p = 0.0107 · Odds ratio (or): 2.3 · 95% CI 1.2 to 4.4
  • Deucravacitinib vs Placebo · Stratified Cochran-Mantel-Haenszel (CMH) · p = 0.0175 · Odds ratio (or): 2.3 · 95% CI 1.2 to 4.7
SecondaryChange From Baseline in Whole-body Itch Numerical Rating Scale (NRS) Score at Week 16

The whole-body itch Numerical Rating Scale (NRS) is a survey that participants fill out themselves. It uses an 11-point scale from 0 to 10, where 0 means 'no itch' and 10 means 'worst itch imaginable.' Participants indicate the severity of their itching from psoriasis by selecting the number that best describes the worst level of itching they experienced in the past 24 hours. A lower score means better outcomes, indicating less severe itching.

Time frame:
Baseline and at Week 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Whole-body Itch Numerical Rating Scale (NRS) Score at Week 16
Score on a ScaleDeucravacitinibPlacebo
Full Analysis Set-3.8 ± 2.86-1.8 ± 2.78
Full Analysis Set Sub-population-3.8 ± 2.73-1.8 ± 2.70
Statistical analysis
  • Deucravacitinib vs Placebo · Covariance model · p = <0.0001 · Adjusted mean difference: -2.0 · 95% CI -2.9 to -1.2
  • Deucravacitinib vs Placebo · Covariance model · p = <0.0001 · Adjusted mean difference: -2.2 · 95% CI -3.0 to -1.3
SecondaryPercentage of Participants With a Static Physician's Global Assessment (s-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16

The Static Physician's Global Assessment (s-PGA) is a 5-point scale to evaluate the average severity of all psoriatic lesions based on redness, scaling, and thickness. The s-PGA measures psoriasis severity at a single point in time, without considering the initial condition. The scale rates the severity as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). A lower score means better outcomes, indicating less severe psoriasis.

Time frame:
At Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Static Physician's Global Assessment (s-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 16
Percentage of ParticipantsDeucravacitinibPlacebo
Percentage of Participants With a Static Physician's Global Assessment (s-PGA) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-point Reduction From Baseline at Week 1635.5 (26.5 to 45.4)8.2 (2.3 to 19.6)
Statistical analysis
  • Deucravacitinib vs Placebo · Stratified Cochran-Mantel-Haenszel (CMH) · p = 0.0004 · Odds ratio (or): 5.9 · 95% CI 2.0 to 17.4
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs) From Week 0 to Week 16

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

Time frame:
From Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) From Week 0 to Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants With Treatment Emergent Adverse Events (AEs) From Week 0 to Week 166325
SecondaryNumber of Participants With Treatment Emergent Serious Adverse Events (SAEs) From Week 0 to Week 16

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) From Week 0 to Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) From Week 0 to Week 1631
SecondaryNumber of Participants With Laboratory Abnormalities in Potential Drug-Induced Liver Injury Tests From Week 0 to Week 16

Number of participants with laboratory abnormalities in potential drug-induced liver injury tests. ALT=Alanine aminotransferase AST=Aspartate aminotransferase ULN=Upper limit of normal

Time frame:
From Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities in Potential Drug-Induced Liver Injury Tests From Week 0 to Week 16
ParticipantsDeucravacitinibPlacebo
ALT or AST > 3 X ULN10
ALT or AST > 5 X ULN00
Total Bilirubin > 2 X ULN00
ALT or AST > 3 X ULN and Total Bilirubin > 2 X ULN on the same day00
SecondaryNumber of Participants With Grade 3/ Grade 4 Laboratory Abnormalities From Week 0 to Week 16

Blood samples were collected to assess the abnormalities in laboratory parameters. The laboratory parameters were graded by Common Terminology Criteria for Adverse Events (CTCAE). Grade 3=Severe; Grade 4=Life-threatening.

Time frame:
From Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Grade 3/ Grade 4 Laboratory Abnormalities From Week 0 to Week 16
ParticipantsDeucravacitinibPlacebo
Hematology: Leukocytes (Grade 3)10
Hematology: Platelets (Grade 4)10
Chemistry: Potassium (Grade 3)10
SecondaryNumber of Participants With Abnormalities in Vital Signs From Week 0 to Week 16

Number of participants with abnormalities in vital signs including heart rate, systolic blood pressure, and diastolic blood pressure.

Time frame:
From Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Vital Signs From Week 0 to Week 16
ParticipantsDeucravacitinibPlacebo
Heart Rate (Beats/Min): Value > 100 And Change From Baseline > 3001
Heart Rate (Beats/Min): Value < 55 And Change From Baseline < -1500
Heart Rate (Beats/Min): Not Reported00
Systolic Blood Pressure (Mmhg): Value > 140 And Change From Baseline > 2054
Systolic Blood Pressure (Mmhg): Value < 90 And Change From Baseline < -2000
Systolic Blood Pressure (Mmhg): Not Reported00
Diastolic Blood Pressure (Mmhg): Value > 90 And Change From Baseline > 10196
Diastolic Blood Pressure (Mmhg): Value < 55 And Change From Baseline < -1001
Diastolic Blood Pressure (Mmhg): Not Reported00
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs From Week 0 to Week 16

Vital Sign Measurements include: Body Temperature (C), Respiratory Rate (breaths/min), Seated Blood Pressure (mmHg) and Heart Rate (beats/min). Clinically significant changes in these measurements may need medical attention as they could indicate a potential health concern.

Time frame:
From Week 0 through Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs From Week 0 to Week 16
ParticipantsDeucravacitinibPlacebo
Number of Participants With Clinically Significant Changes in Vital Signs From Week 0 to Week 1600

Adverse events

Collected over Participants were assessed for All-cause mortality, Serious adverse events and Other adverse events for up to approximately 28 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Controlled - Deucravacitinib1/119 (0.8%)3/119 (2.5%)32/119 (26.9%)
Placebo Controlled - Placebo0/59 (0%)1/59 (1.7%)13/59 (22%)
Active Treatment - Deucravacitinib - Deucravacitinib1/103 (1%)5/103 (4.9%)26/103 (25.2%)
Active Treatment - Placebo - Deucravacitinib0/49 (0%)3/49 (6.1%)10/49 (20.4%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlacebo Controlled - DeucravacitinibPlacebo Controlled - PlaceboActive Treatment - Deucravacitinib - DeucravacitinibActive Treatment - Placebo - Deucravacitinib
CholelithiasisHepatobiliary disorders0/1190/590/1031/49
PneumoniaInfections and infestations0/1190/592/1031/49
Postoperative wound infectionInfections and infestations0/1190/590/1031/49
Angina pectorisCardiac disorders0/1191/590/1030/49
Acute coronary syndromeCardiac disorders0/1190/591/1030/49
Cardiac failure congestiveCardiac disorders0/1190/591/1030/49
Chest painGeneral disorders0/1190/591/1030/49
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1190/591/1030/49
Vertigo positionalEar and labyrinth disorders1/1190/590/1030/49
DeathGeneral disorders1/1190/590/1030/49
Most frequent other events
Most frequent other events
EventPlacebo Controlled - DeucravacitinibPlacebo Controlled - PlaceboActive Treatment - Deucravacitinib - DeucravacitinibActive Treatment - Placebo - Deucravacitinib
COVID-19Infections and infestations7/1192/5910/1032/49
Upper respiratory tract infectionInfections and infestations4/1193/598/1031/49
AcneSkin and subcutaneous tissue disorders9/1190/593/1032/49
NasopharyngitisInfections and infestations8/1192/594/1032/49
CoughRespiratory, thoracic and mediastinal disorders1/1191/593/1033/49
HeadacheNervous system disorders2/1193/592/1031/49
Nasal congestionRespiratory, thoracic and mediastinal disorders1/1193/593/1030/49
SinusitisInfections and infestations6/1190/590/1030/49

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DeucravacitinibPlaceboTotal
Mean49.1 ± 14.9247.5 ± 13.5548.6 ± 14.46
Sex: Female, Male
Sex: Female, Male(Participants)DeucravacitinibPlaceboTotal
Female482068
Male7240112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DeucravacitinibPlaceboTotal
Hispanic or Latino342256
Not Hispanic or Latino8636122
Unknown or Not Reported022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DeucravacitinibPlaceboTotal
American Indian or Alaska Native000
Asian516
Black or African American369
Native Hawaiian or Other Pacific Islander101
White10850158
Other235
Unknown or Not Reported101
08

Study locations

38 sites
  • Local Institution - 0006
    Phoenix, Arizona 85006, United States
  • Local Institution - 0034
    Scottsdale, Arizona 85260, United States
  • Local Institution - 0015
    North Little Rock, Arkansas 72117, United States
  • Local Institution - 0004
    Bakersfield, California 93309, United States
  • Local Institution - 0009
    Sacramento, California 95815, United States
  • Local Institution - 0022
    San Diego, California 92103, United States
  • Local Institution - 0030
    Centennial, Colorado 80111, United States
  • Local Institution - 0024
    Washington D.C., District of Columbia 20016, United States
  • Local Institution - 0027
    Brandon, Florida 33511, United States
  • Local Institution - 0016
    Coral Gables, Florida 33134, United States
  • Riverchase Dermatology
    Pembroke Pines, Florida 33028, United States
  • Local Institution - 0037
    Atlanta, Georgia 30331, United States
  • Local Institution - 0020
    Snellville, Georgia 30078, United States
  • Local Institution - 0007
    Rolling Meadows, Illinois 60008, United States
  • Local Institution - 0025
    Skokie, Illinois 60077, United States
  • Local Institution - 0036
    Springfield, Illinois 62703, United States
  • Local Institution - 0003
    Baton Rouge, Louisiana 70809, United States
  • Local Institution - 0018
    Rockville, Maryland 20850, United States
  • Local Institution - 0010
    Auburn Hills, Michigan 48326, United States
  • Local Institution - 0002
    Waterford, Michigan 48328, United States
  • Local Institution - 0017
    Las Vegas, Nevada 89148, United States
  • Local Institution - 0035
    Reno, Nevada 89509, United States
  • Local Institution - 0032
    New York, New York 10011, United States
  • Local Institution - 0013
    New York, New York 10128, United States
  • Local Institution - 0001
    Rochester, New York 14623, United States
  • Local Institution - 0005
    Bexley, Ohio 43209, United States
  • Local Institution - 0012
    Mayfield Heights, Ohio 44124, United States
  • Local Institution - 0019
    Charleston, South Carolina 29407, United States
  • Local Institution - 0029
    Cypress, Texas 77433, United States
  • Local Institution - 0028
    Frisco, Texas 75034, United States
  • Local Institution - 0008
    South Jordan, Utah 84095, United States
  • Local Institution - 0033
    Springville, Utah 84663, United States
  • Local Institution - 0021
    Bellevue, Washington 98004, United States
  • Local Institution - 0031
    Mill Creek, Washington 98012, United States
  • Local Institution - 0014
    Spokane, Washington 99202, United States
  • Local Institution - 0040
    Caguas, 00727, Puerto Rico
  • Local Institution - 0038
    Carolina, 00985, Puerto Rico
  • Local Institution - 0039
    San Juan, 00917, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol-Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Aug 2024, 18 months.

Results were first posted in Sep 2025, 1 year after primary completion.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 18 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2023
First posted
Jan 27, 2023
StartActual
Jan 31, 2023
Primary completionActual
Aug 23, 2024
CompletionActual
May 29, 2025
Results first posted
Sep 10, 2025
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05701995
Responsible party
Sponsor
First posted
Jan 27, 2023
Start date
Jan 31, 2023
Primary completion
Aug 23, 2024
Completion
May 29, 2025
Results posted
Sep 10, 2025
Last update
Jun 3, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion